Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
Authors:
- Nicola SilvestrisNicola Silvestris
- Oronzo BrunettiOronzo Brunetti
- Alessandro BittoniABAlessandro Bittoni
- Ivana CataldoICIvana Cataldo
- Domenico CorsiDCDomenico Corsi
- Stefano CrippaSCStefano Crippa
- Mirko D’onofrioMirko D’onofrio
- Michele FioreMFMichele Fiore
- Elisa GiommoniEGElisa Giommoni
- Michele MilellaMMMichele Milella
- Raffaele PezzilliRaffaele Pezzilli
- Enrico VasileEVEnrico Vasile
Open Access
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.Keywords
This publication has 74 references indexed in Scilit:
- Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness AnalysisAnnals of Surgical Oncology, 2013
- Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapyHPB, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III TrialAnnals of Surgical Oncology, 2011
- Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II StudyJournal of Clinical Oncology, 2010
- Anthropometric Measures, Body Mass Index, and Pancreatic CancerArchives of internal medicine (1960), 2010
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerBritish Journal of Cancer, 2009
- Preoperative evaluation of pancreatic cancer: Comparison of gadolinium‐enhanced dynamic MRI with MR cholangiopancreatography versus MDCTJournal of Magnetic Resonance Imaging, 2009
- Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic ReviewJournal of Clinical Oncology, 2009
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004